Intermedin1‑53 enhances angiogenesis and attenuates adverse remodeling following myocardial infarction by activating AMP‑activated protein kinase

Chen,Kankai; Yan,Meiling; Li,Yongguang; Dong,Zhifeng; Huang,Dong; Li,Jingbo; Wei,Meng

doi:10.3892/mmr.2017.6193

Intermedin1‑53 enhances angiogenesis and attenuates adverse remodeling following myocardial infarction by activating AMP‑activated protein kinase

Authors:
- Kankai Chen
- Meiling Yan
- Yongguang Li
- Zhifeng Dong
- Dong Huang
- Jingbo Li
- Meng Wei
View Affiliations

Affiliations: Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China
Published online on: February 10, 2017 https://doi.org/10.3892/mmr.2017.6193
Pages: 1497-1506
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adverse ventricular remodeling is a maladaptive response to acute loss of myocardium and an important risk factor for heart failure following myocardial infarction (MI). Intermedin (IMD) is a novel member of the calcitonin/calcitonin gene‑related peptide family, which may possess potent cardioprotective properties. The aim of the present study was to determine whether IMD1‑53, a mature bioactive form of IMD, may promote therapeutic angiogenesis within the infarcted myocardium, therefore attenuating adverse ventricular remodeling post‑MI. The present study observed that treatment with IMD1‑53 promoted proliferation, migration and tube formation of primary cultured myocardial microvascular endothelial cells (MMVECs). In a rat model of MI, chronic administration of IMD1‑53 increased capillary density in the peri‑infarct zone, attenuated ventricular remodeling and improved cardiac performance post‑MI. Treatment with IMD1‑53 also significantly increased the expression levels of phosphorylated‑AMP‑activated protein kinase (AMPK) and the subsequent activation of endothelial nitric oxide synthase in MMVECs and post‑MI rat myocardium, without a significant influence on the expression of vascular endothelial growth factor. Notably, the in vitro effects of IMD1‑53 on angiogenesis and the in vivo effects of IMD1‑53 on post‑MI ventricular remodeling were largely abrogated by the co‑administration of compound C, an AMPK inhibitor. In conclusion, the present study demonstrated that IMD1‑53 could attenuate adverse ventricular remodeling post‑MI via the promotion of therapeutic angiogenesis, possibly through the activation of AMPK signaling.

View Figures

View References

1	Pfeffer MA and Braunwald E: Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 81:1161–1172. 1990. View Article : Google Scholar : PubMed/NCBI
2	Jessup M and Brozena S: Heart failure. N Engl J Med. 348:2007–2018. 2003. View Article : Google Scholar : PubMed/NCBI
3	Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, De Ferranti S, Després JP, Fullerton HJ, Howard VJ, et al: Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation. 131:e29–e322. 2015. View Article : Google Scholar : PubMed/NCBI
4	Oka T, Akazawa H, Naito AT and Komuro I: Angiogenesis and cardiac hypertrophy: Maintenance of cardiac function and causative roles in heart failure. Circ Res. 114:565–571. 2014. View Article : Google Scholar : PubMed/NCBI
5	Yang JH, Jia YX, Pan CS, Zhao J, Ouyang M, Yang J, Chang JK, Tang CS and Qi YF: Effects of intermedin(1–53) on cardiac function and ischemia/reperfusion injury in isolated rat hearts. Biochem Biophys Res Commun. 327:713–719. 2005. View Article : Google Scholar : PubMed/NCBI
6	Zhao L, Peng DQ, Zhang J, Song JQ, Teng X, Yu YR, Tang CS and Qi YF: Extracellular signal-regulated kinase 1/2 activation is involved in intermedin1-53 attenuating myocardial oxidative stress injury induced by ischemia/reperfusion. Peptides. 33:329–335. 2012. View Article : Google Scholar : PubMed/NCBI
7	Yang X, Zhang H, Jia Y, Ni L, Li G, Xue L and Jiang Y: Effects of intermedin1-53 on myocardial fibrosis. Acta Biochim Biophys Sin (Shanghai). 45:141–148. 2013. View Article : Google Scholar : PubMed/NCBI
8	Chen H, Wang X, Tong M, Wu D, Wu S, Chen J, Wang X, Wang X, Kang Y, Tang H, et al: Intermedin suppresses pressure overload cardiac hypertrophy through activation of autophagy. PLoS One. 8:e647572013. View Article : Google Scholar : PubMed/NCBI
9	Lu WW, Zhao L, Zhang JS, Hou YL, Yu YR, Jia MZ, Tang CS and Qi YF: Intermedin1-53 protects against cardiac hypertrophy by inhibiting endoplasmic reticulum stress via activating AMP-activated protein kinase. J Hypertens. 33:1676–1687. 2015. View Article : Google Scholar : PubMed/NCBI
10	Smith RS Jr, Gao L, Bledsoe G, Chao L and Chao J: Intermedin is a new angiogenic growth factor. Am J Physiol Heart Circ Physiol. 297:H1040–H1047. 2009. View Article : Google Scholar : PubMed/NCBI
11	Zhang W, Wang LJ, Xiao F, Wei Y, Ke W and Xin HB: Intermedin: A novel regulator for vascular remodeling and tumor vessel normalization by regulating vascular endothelial-cadherin and extracellular signal-regulated kinase. Arterioscler Thromb Vasc Biol. 32:2721–2732. 2012. View Article : Google Scholar : PubMed/NCBI
12	Derumeaux G, Mulder P, Richard V, Chagraoui A, Nafeh C, Bauer F, Henry JP and Thuillez C: Tissue Doppler imaging differentiates physiological from pathological pressure-overload left ventricular hypertrophy in rats. Circulation. 105:1602–1608. 2002. View Article : Google Scholar : PubMed/NCBI
13	Wang F, Huang D, Zhu W, Li S, Yan M, Wei M and Li J: Selective inhibition of PKCβ2 preserves cardiac function after myocardial infarction and is associated with improved angiogenesis of ischemic myocardium in diabetic rats. Int J Mol Med. 32:1037–1046. 2013.PubMed/NCBI
14	Nagata D, Mogi M and Walsh K: AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem. 278:31000–31006. 2003. View Article : Google Scholar : PubMed/NCBI
15	Yang JH, Pan CS, Jia YX, Zhang J, Zhao J, Pang YZ, Yang J, Tang CS and Qi YF: Intermedin1-53 activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Biochem Biophys Res Commun. 341:567–572. 2006. View Article : Google Scholar : PubMed/NCBI
16	Roh J, Chang CL, Bhalla A, Klein C and Hsu SY: Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem. 279:7264–7274. 2004. View Article : Google Scholar : PubMed/NCBI
17	Sutton MG and Sharpe N: Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation. 101:2981–2988. 2000. View Article : Google Scholar : PubMed/NCBI
18	Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM and Itescu S: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 7:430–436. 2001. View Article : Google Scholar : PubMed/NCBI
19	Li J, Zhang Y, Li C, Xie J, Liu Y, Zhu W, Zhang X, Jiang S, Liu L and Ding Z: HSPA12B attenuates cardiac dysfunction and remodelling after myocardial infarction through an eNOS-dependent mechanism. Cardiovasc Res. 99:674–684. 2013. View Article : Google Scholar : PubMed/NCBI
20	Vandoorne K, Vandsburger MH, Raz T, Shalev M, Weisinger K, Biton I, Brumfeld V, Raanan C, Nevo N, Eilam R, et al: Chronic Akt1 deficiency attenuates adverse remodeling and enhances angiogenesis after myocardial infarction. Circ Cardiovasc Imaging. 6:992–1000. 2013. View Article : Google Scholar : PubMed/NCBI
21	Zhao X, Balaji P, Pachon R, Beniamen DM, Vatner DE, Graham RM and Vatner SF: Overexpression of cardiomyocyte α1A-Adrenergic receptors attenuates postinfarct remodeling by inducing angiogenesis through heterocellular signaling. Arterioscler Thromb Vasc Biol. 35:2451–2459. 2015. View Article : Google Scholar : PubMed/NCBI
22	Grahame Hardie D: AMP-activated protein kinase: A key regulator of energy balance with many roles in human disease. J Intern Med. 276:543–559. 2014. View Article : Google Scholar : PubMed/NCBI
23	Ahluwalia A and Tarnawski AS: Activation of the metabolic sensor-AMP activated protein kinase reverses impairment of angiogenesis in aging myocardial microvascular endothelial cells. Implications for the aging heart. J Physiol Pharmacol. 62:583–587. 2011.PubMed/NCBI
24	Izumi Y, Shiota M, Kusakabe H, Hikita Y, Nakao T, Nakamura Y, Muro T, Miura K, Yoshiyama M and Iwao H: Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. Hypertens Res. 32:675–679. 2009. View Article : Google Scholar : PubMed/NCBI
25	Shimano M, Ouchi N, Shibata R, Ohashi K, Pimentel DR, Murohara T and Walsh K: Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J Mol Cell Cardiol. 49:210–220. 2010. View Article : Google Scholar : PubMed/NCBI
26	Su KH, Yu YB, Hou HH, Zhao JF, Kou YR, Cheng LC, Shyue SK and Lee TS: AMP-activated protein kinase mediates erythropoietin-induced activation of endothelial nitric oxide synthase. J Cell Physiol. 227:3053–3062. 2012. View Article : Google Scholar : PubMed/NCBI
27	Zheng S, Li W, Xu M, Bai X, Zhou Z, Han J, Shyy JY and Wang X: Calcitonin gene-related peptide promotes angiogenesis via AMP-activated protein kinase. Am J Physiol Cell Physiol. 299:C1485–C1492. 2010. View Article : Google Scholar : PubMed/NCBI